6-Methyleneandrost-4-ene-3,17-Dione CAS 19457-55-7 Exemestane Intermediate Purity >99.0% (HPLC) Factory
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 6-Methyleneandrost-4-ene-3,17-Dione (1,2-Dihydro Exemestane) (CAS: 19457-55-7) with high quality, intermediate of Exemestane (CAS: 107868-30-4). We can provide COA, worldwide delivery, small and bulk quantities available. If you are interested in 6-Methyleneandrost-4-ene-3,17-Dione, Please contact: alvin@ruifuchem.com
Chemical Name | 6-Methyleneandrost-4-ene-3,17-Dione |
Synonyms | 1,2-Dihydro Exemestane; 6-Methylene-4-Androstene-3,17-Dione |
Impurity | Exemestane EP Impurity E; Exemestane USP Related Compound A |
Stock Status | In Stock, Production Capacity 20 Tons per Month |
CAS Number | 19457-55-7 |
Molecular Formula | C20H26O2 |
Molecular Weight | 298.43 |
Melting Point | ≥158.0℃ |
Boiling Point | 450.8±45.0℃ |
Density | 1.11±0.1 g/cm3 |
Specific Rotation [α]20/D | +390.0° to +430.0° (C=1, CHCL3) |
Storage Temp. |
Store at Room Temperature |
HS Code | 2937290099 |
COA & MSDS | Available |
Classification | Steroids Compound |
Brand | Ruifu Chemical |
Items |
Specifications |
Results |
Appearance |
Pale Yellow Crystalline Powder |
Conform |
Identification |
A: IR; B: RT (HPLC) |
Conform |
Melting Point |
≥158℃ |
161℃ |
Related Substances (HPLC) |
|
|
Relative Retention Time=0.81 |
<0.40% |
0.17% |
Relative Retention Time=1.34 |
<0.40% |
Conform |
Unknown Individual |
<0.10% |
0.03% |
Total Impurities |
<1.00% |
0.29% |
Loss on Drying |
<0.50% |
0.05% |
Purity / Analysis Method |
>99.0% |
99.71% |
Infrared Spectrum | Conforms to Structure | |
Test Standard |
Enterprise Standard | |
Main Usage |
Intermediate/Impurity of Exemestane (CAS: 107868-30-4) |
Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool, dry and ventilated warehouse away from incompatible substances. Protect from light and moisture.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
6-Methyleneandrost-4-ene-3,17-Dione (1,2-Dihydro Exemestane) (CAS: 19457-55-7) is an intermediate / impurity of Exemestane (CAS: 107868-30-4). Exemestane is an irreversible steroid aromatase inhibitor. Its structure is similar to that of aromatase’s natural substrate, androstenedione, and acts as a pseudosubstrate. Postmenopausal women’s estrogen is mainly converted from androgen (produced by the adrenal cortex) by aromatase in the surrounding tissue. This drug irreversibly binds with the active site on aromatase to deactivate it, thus dramatically lower estrogen levels in the blood circulation of postmenopausal women. By inhibiting aromatase to lower estrogen levels, it can be used to treat hormone-dependent breast cancer in postmenopausal women.